Literature DB >> 16093386

Use-dependent inhibition of P2X3 receptors by nanomolar agonist.

Emily B Pratt1, Thaddeus S Brink, Pamela Bergson, Mark M Voigt, Sean P Cook.   

Abstract

P2X3 receptors desensitize within 100 ms of channel activation, yet recovery from desensitization requires several minutes. The molecular basis for this slow rate of recovery is unknown. We designed experiments to test the hypothesis that this slow recovery is attributable to the high affinity (< 1 nM) of desensitized P2X3 receptors for agonist. We found that agonist binding to the desensitized state provided a mechanism for potent inhibition of P2X3 current. Sustained applications of 0.5 nM ATP inhibited > 50% of current to repetitive applications of P2X3 agonist. Inhibition occurred at 1000-fold lower agonist concentrations than required for channel activation and showed strong use dependence. No inhibition occurred without previous activation and desensitization. Our data are consistent with a model whereby inhibition of P2X3 by nanomolar [agonist] occurs by the rebinding of agonist to desensitized channels before recovery from desensitization. For several ATP analogs, the concentration required to inhibit P2X3 current inversely correlated with the rate of recovery from desensitization. This indicates that the affinity of the desensitized state and recovery rate primarily depend on the rate of agonist unbinding. Consistent with this hypothesis, unbinding of [32P]ATP from desensitized P2X3 receptors mirrored the rate of recovery from desensitization. As expected, disruption of agonist binding by site-directed mutagenesis increased the IC50 for inhibition and increased the rate of recovery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16093386      PMCID: PMC6725291          DOI: 10.1523/JNEUROSCI.5189-04.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  23 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

2.  Sensing muscle ischemia: coincident detection of acid and ATP via interplay of two ion channels.

Authors:  William T Birdsong; Leonardo Fierro; Frank G Williams; Valeria Spelta; Ligia A Naves; Michelle Knowles; Josephine Marsh-Haffner; John P Adelman; Wolfhard Almers; Robert P Elde; Edwin W McCleskey
Journal:  Neuron       Date:  2010-11-18       Impact factor: 17.173

Review 3.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

4.  P2X3 receptor gating near normal body temperature.

Authors:  V Khmyz; O Maximyuk; V Teslenko; A Verkhratsky; O Krishtal
Journal:  Pflugers Arch       Date:  2007-11-20       Impact factor: 3.657

5.  Cutaneous sensory neurons expressing the Mrgprd receptor sense extracellular ATP and are putative nociceptors.

Authors:  G Dussor; M J Zylka; D J Anderson; E W McCleskey
Journal:  J Neurophysiol       Date:  2008-01-30       Impact factor: 2.714

6.  Activation of P2X7 receptors in glial satellite cells reduces pain through downregulation of P2X3 receptors in nociceptive neurons.

Authors:  Yong Chen; Xiaofei Zhang; Congying Wang; Guangwen Li; Yanping Gu; Li-Yen Mae Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-22       Impact factor: 11.205

Review 7.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

8.  The nicotinic α6 subunit gene determines variability in chronic pain sensitivity via cross-inhibition of P2X2/3 receptors.

Authors:  Jeffrey S Wieskopf; Jayanti Mathur; Walrati Limapichat; Michael R Post; Mona Al-Qazzaz; Robert E Sorge; Loren J Martin; Dmitri V Zaykin; Shad B Smith; Kelen Freitas; Jean-Sebastien Austin; Feng Dai; Jie Zhang; Jaclyn Marcovitz; Alexander H Tuttle; Peter M Slepian; Sarah Clarke; Ryan M Drenan; Jeff Janes; Shakir Al Sharari; Samantha K Segall; Eske K Aasvang; Weike Lai; Reinhard Bittner; Christopher I Richards; Gary D Slade; Henrik Kehlet; John Walker; Uwe Maskos; Jean-Pierre Changeux; Marshall Devor; William Maixner; Luda Diatchenko; Inna Belfer; Dennis A Dougherty; Andrew I Su; Sarah C R Lummis; M Imad Damaj; Henry A Lester; Ardem Patapoutian; Jeffrey S Mogil
Journal:  Sci Transl Med       Date:  2015-05-13       Impact factor: 17.956

Review 9.  Anticancer, antimicrobial, and analgesic activities of spider venoms.

Authors:  Hassan M Akef
Journal:  Toxicol Res (Camb)       Date:  2018-03-08       Impact factor: 3.524

10.  Subtype-specific mechanisms for functional interaction between α6β4* nicotinic acetylcholine receptors and P2X receptors.

Authors:  Walrati Limapichat; Dennis A Dougherty; Henry A Lester
Journal:  Mol Pharmacol       Date:  2014-06-25       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.